Barts and The London School of Medicine and Dentistry

RS BioTherapeutics Promotes Michelle L. Shuffett, MD to Chief Medical Officer

Retrieved on: 
Tuesday, October 31, 2023
Knowledge, University, Children's Hospital Los Angeles, London, Medicine, Barts and The London School of Medicine and Dentistry, Born This Way Foundation, MD, TEC, Bureau of Oceans and International Environmental and Scientific Affairs, Organization, Health, Research, IPF, Senior, RS, Boehringer Ingelheim, Everyday Health, Idiopathic disease, UCLA Mattel Children's Hospital, NIH, Patient, Hospital, COPD, Idiopathic pulmonary fibrosis, Child, Pharmaceutical industry, Nursing, Economics

CUMBERLAND, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce that it has appointed Michelle L. Shuffett, MD as its Chief Medical Officer.

Key Points: 
  • CUMBERLAND, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is pleased to announce that it has appointed Michelle L. Shuffett, MD as its Chief Medical Officer.
  • Commenting on the promotion of Dr. Shuffett to Chief Medical Officer, Dean Hart, Chief Executive Officer of RS BioTherapeutics said, “Michelle has been a tremendous addition to our leadership team.
  • Michelle will Chair the TEC and that group will help guide the development of RSBT-001.”
    Commenting on her appointment, Dr. Shuffett said, “I’m thrilled to continue working with the incredible leadership team at RS BioTherapeutics in this new role.
  • Dr. Shuffett has also served in senior roles at several organizations including Synapse Medical Communications, Everyday Health, Columbia Care, and Radicle Science.

Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

Retrieved on: 
Sunday, October 22, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Neoplasm, Appetite, DXD, PRS, PD-L1, Constipation, AstraZeneca, PD, Vomiting, Stomatitis, Congress, European Society for Medical Oncology, PFS, MD, CRS, HIV disease progression rates, TNBC, ADC, Dor, TSE, Breast cancer, ORR, ILD, Arm, Patient, Breast, Barts and The London School of Medicine and Dentistry, Fatigue, Medical imaging, Pharmaceutical industry, Daiichi Sankyo, Durvalumab

Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Key Points: 
  • Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).
  • “These results for datopotamab deruxtecan plus durvalumab in the first-line triple negative breast cancer setting are highly encouraging, particularly the 79% objective response rate,” said Peter Schmid, MD, Barts Cancer Institute, London, United Kingdom, and investigator in the trial.
  • “Disease progression after initial treatment is a reality for patients with triple negative breast cancer, underscoring the need for more durable treatment options,” said Mark Rutstein, MD, Global Head, Oncology Clinical Development, Daiichi Sankyo.
  • As of the February 2, 2023 data cut-off, 29 patients (47%) remained on study treatment.

OMass Therapeutics Expands Leadership Team with Two New Appointments

Retrieved on: 
Wednesday, August 2, 2023
CASE, GSK, UCL, Royal college, Central nervous system, University, University of London, OSI Pharmaceuticals, Senior, Oxford, Biotechnology, Pharmacognosy, University of Cambridge, ARC, Drug, GW Pharmaceuticals, Royal London Hospital, Internal medicine, Biology, AstraZeneca, Manchester Metropolitan University, Psoriasis, Development, UCB, Shire (pharmaceutical company), Weapon Shop de Omasse, Novartis, DMPK, Toxicology, Imperial College London, MRCP, NHS, Rare, Therapy, Membership of the Royal Colleges of Physicians of the United Kingdom, Safety, Barts and The London School of Medicine and Dentistry, Management, Pharmaceutical industry, Pharmacology, Pfizer

Peter Phillips M.D., Ph.D. has joined as Senior Vice President of Clinical Development and Julia Sampson Ph.D. as Vice President of Non-clinical Development.

Key Points: 
  • Peter Phillips M.D., Ph.D. has joined as Senior Vice President of Clinical Development and Julia Sampson Ph.D. as Vice President of Non-clinical Development.
  • “Both Peter and Julia have a huge amount of experience in taking programs from preclinical through to clinical development and I am hugely excited about what they will bring to the OMass team,” said Ros Deegan, CEO of OMass Therapeutics.
  • “With our solid financial backing and new expanded facilities, we are growing our team strategically as we advance our pipeline of exciting early-stage assets in immunology and rare diseases.
  • In her most recent role at Kalvista Pharmaceuticals, she was responsible for strategy, leadership, recruitment and management of the non-clinical safety assessment team, leading toxicology, safety pharmacology and DMPK functions.

Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis

Retrieved on: 
Wednesday, May 31, 2023
Railway Workers' Union (Austria), Macrophage, Barts and The London School of Medicine and Dentistry, Week, Disability, Research, Multiple sclerosis, CMSC, Queen Mary University of London, MS, St. Bartholomew's, Patient, Sanofi, Dentistry, Pivotal, CD40L, B cell, Blizard Building, Pharmaceutical industry, Vaccine, Neurology

Frexalimab met primary endpoint with 89% reduction in new gadolinium-enhancing T1 brain lesions achieved at Week 12 in the higher-dose treatment arm, compared with placebo

Key Points: 
  • Frexalimab met primary endpoint with 89% reduction in new gadolinium-enhancing T1 brain lesions achieved at Week 12 in the higher-dose treatment arm, compared with placebo
    Paris, May 31 2023.
  • New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational anti-CD40L antibody, with a unique mechanism of action, significantly reduced disease activity in a Phase 2 trial of patients with relapsing multiple sclerosis (MS).
  • Following 12 weeks of therapy, the number of new gadolinium-enhancing (GdE) T1-lesions was reduced by 89% and 79% in the higher- and lower-dose treatment arms, respectively, compared with placebo, meeting the study’s primary endpoint.
  • A substantial unmet need remains in MS for highly effective and well-tolerated treatment options that provide sustainable control of disease activity and disability progression, while minimizing risks.

AirSculpt® Technologies, Inc. Announces Plans to Open London Location in 2023

Retrieved on: 
Tuesday, December 13, 2022
General surgery, Surgeon, Barts and The London School of Medicine and Dentistry, Skin, Bruise, MIAMI, Harley Street, MAK Technologies, Inc., Medical director, University, Dentistry

AirSculpt now expects to open five office locations in 2023.

Key Points: 
  • AirSculpt now expects to open five office locations in 2023.
  • AirSculpt® is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at Elite Body Sculpture offices.
  • “We are delighted to share that we will be opening our first overseas location during the first half of 2023,” said Dr. Aaron Rollins, Founder and Chief Executive Officer at AirSculpt® Technologies.
  • He qualified from The London Hospital Medical College (University of London) and trained in General Surgery and Plastic Surgery predominantly in London teaching hospitals.

Envisagenics, Cancer Research Horizons, and Queen Mary University of London Announce Strategic Collaboration Agreement

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, Genome, Therapy, Barts and The London School of Medicine and Dentistry, Lymphatic system, Queen Mary University of London, Cold, National Cancer Institute, Drug discovery, Patient, National Institute of General Medical Sciences, Student, Research, Precision medicine, Disease, RNA splicing, Cancer Research UK, Genomics, AML, Cold Spring Harbor Laboratory, Artificial intelligence, University, Proteomics, Acute myeloid leukemia, Neurodegeneration, Cancer research, Hope, Machine learning, RNA, Alternative splicing, Social mobility, Algorithm, Organization, Pharmaceutical industry, Cancer

NEW YORK, Dec. 13, 2022 /PRNewswire/ -- Envisagenics, an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Cancer Research Horizons, Cancer Research UK's innovation engine, and Queen Mary University of London. Envisagenics will leverage its SpliceCore® AI platform and use Queen Mary's de-identified data to further explore the role of alternative splicing in hematopoietic cancers for research and development.

Key Points: 
  • NEW YORK, Dec. 13, 2022 /PRNewswire/ -- Envisagenics , an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Cancer Research Horizons , Cancer Research UK's innovation engine, and Queen Mary University of London .
  • Cancer Research Horizons is the innovation engine of Cancer Research UK the world's largest charitable funder of cancer research.
  • We've helped bring 11 cancer drugs to market, borne out of Cancer Research UK's pioneering research.
  • Queen Mary University of London is a leading research-intensive university with a difference one that opens the doors of opportunity to anyone with the potential to succeed.

VacV Biotherapeutics emerges from stealth mode to bring ground-breaking cancer immunotherapies to the clinic

Retrieved on: 
Wednesday, October 26, 2022
Company, Virus, Cancer, Recurrence, Glioblastoma, Immunotherapy, Neoplasm, Tumor microenvironment, Barts and The London School of Medicine and Dentistry, Patient, Oncolytic virus, Research, Potyvirus, Queen Mary University of London, Pharmaceutical industry, Vaccine, Vaccinia

The Company has already attracted a $3 million investment from Proxima Ventures, which it has used to complete preclinical studies and build the team.

Key Points: 
  • The Company has already attracted a $3 million investment from Proxima Ventures, which it has used to complete preclinical studies and build the team.
  • Immunotherapies, which enable a patients immune systemto recognize and target cancer cells, have made a significant difference to cancer patients over the last decade.
  • Oncolytic viruses can directly kill cancer cells, alter the tumor microenvironment and sensitize more patients to immunotherapy.
  • As a pioneer in this space, VacV has generated viruses with optimal payloads and backbones to create a systemically deliverable, targeted, viral-based cancer immunotherapy.

VacV Biotherapeutics emerges from stealth mode to bring ground-breaking cancer immunotherapies to the clinic

Retrieved on: 
Wednesday, October 26, 2022
Company, Virus, Cancer, Recurrence, Glioblastoma, Immunotherapy, Neoplasm, Tumor microenvironment, Barts and The London School of Medicine and Dentistry, Patient, Oncolytic virus, Research, Potyvirus, Queen Mary University of London, Pharmaceutical industry, Vaccine, Vaccinia

The Company has already attracted a $3 million investment from Proxima Ventures, which it has used to complete preclinical studies and build the team.

Key Points: 
  • The Company has already attracted a $3 million investment from Proxima Ventures, which it has used to complete preclinical studies and build the team.
  • Immunotherapies, which enable a patients immune systemto recognize and target cancer cells, have made a significant difference to cancer patients over the last decade.
  • Oncolytic viruses can directly kill cancer cells, alter the tumor microenvironment and sensitize more patients to immunotherapy.
  • As a pioneer in this space, VacV has generated viruses with optimal payloads and backbones to create a systemically deliverable, targeted, viral-based cancer immunotherapy.

BenevolentAI Group: Analyst / Investor Event and Interim Results

Retrieved on: 
Friday, September 16, 2022
University of London, Immunology, Barts and The London School of Medicine and Dentistry, Company, Aldersgate, Technology, Euronext Amsterdam, BAI, St. Bartholomew's, FTI Consulting, Dentistry, University, Webcast, Drug discovery

LONDON, Sept. 16, 2022 /PRNewswire/ -- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 17:00 BST (09:00 12:00 ET) on Tuesday, 27 September 2022.

Key Points: 
  • LONDON, Sept. 16, 2022 /PRNewswire/ -- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 17:00 BST (09:00 12:00 ET) on Tuesday, 27 September 2022.
  • The event will be held in person at the offices of FTI Consulting (200 Aldersgate, Aldersgate Street, London, EC1A 4HD, United Kingdom) and will also be accessible via webcast with a presentation recording made available on the Company's website shortly afterwards.
  • At the event, BenevolentAI's executive leadership team will lead sessions about the Company's approach and technology and its positioning within the wider AI drug discovery market, as well as talking about the Company's pipeline and business model.
  • The event will also include an overview of BenevolentAI's interim results for the period ended 30 June 2022.

BenevolentAI Group: Analyst / Investor Event and Interim Results

Retrieved on: 
Friday, September 16, 2022
University of London, Immunology, Barts and The London School of Medicine and Dentistry, Company, Aldersgate, Technology, Euronext Amsterdam, BAI, St. Bartholomew's, FTI Consulting, Dentistry, University, Webcast, Drug discovery

LONDON, Sept. 16, 2022 /PRNewswire/ -- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 17:00 BST (09:00 12:00 ET) on Tuesday, 27 September 2022.

Key Points: 
  • LONDON, Sept. 16, 2022 /PRNewswire/ -- BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, is pleased to announce the full agenda for its upcoming analyst/investor event and interim results being held in London between 14:00 17:00 BST (09:00 12:00 ET) on Tuesday, 27 September 2022.
  • The event will be held in person at the offices of FTI Consulting (200 Aldersgate, Aldersgate Street, London, EC1A 4HD, United Kingdom) and will also be accessible via webcast with a presentation recording made available on the Company's website shortly afterwards.
  • At the event, BenevolentAI's executive leadership team will lead sessions about the Company's approach and technology and its positioning within the wider AI drug discovery market, as well as talking about the Company's pipeline and business model.
  • The event will also include an overview of BenevolentAI's interim results for the period ended 30 June 2022.